With the ink on their $25M Astellas deal still drying, Aquinox shares get blasted on PhIII failure

With the ink on their $25M Astellas deal still drying, Aquinox shares get blasted on PhIII failure

Submitted by CP Staff on June 27, 2018 - 10:21am
Source: 
Endpoints
News Tags: 
Aquinox Pharmaceuticals
Astellas
rosiptor
Asia
clinical trials
Interstitial Cystitis
Headline: 
With the ink on their $25M Astellas deal still drying, Aquinox shares get blasted on PhIII failure
snippet: 

Just weeks after Astellas agreed to pay Aquinox Pharmaceuticals $25 million upfront for Asian rights to their lead drug rosiptor, the little biotech says their Phase III trial was a complete disaster, leaving nothing to salvage.

Do Not Allow Advertisers to Use My Personal information